Literature DB >> 10192451

Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic-specific rates.

M Hickman1, B Modell, P Greengross, C Chapman, M Layton, S Falconer, S C Davies.   

Abstract

A range of estimates for sickle cell and beta thalassaemia have been derived for the different ethnic groups living in the U.K., reflecting uncertainty over the true population value in certain countries and the heterogeneity within and between countries of origin comprising the same ethnic group. These were validated against six community screening programmes, with the estimated range correctly predicting the number of affected births observed by the programmes. In England approximately 3000 affected babies (0.47%) carry sickle cell trait and 2800 (0.44%) carry beta thalassaemia trait annually: with approximately 178 (0.28 per 1000 conceptions) affected by sickle cell disease (SCD) and 43 (0.07 per 1000) by beta thalassaemia major/intermedia. Allowing for termination, about 140-175 (0.22-0.28 per 1000) affected infants are born annually with SCD and from 10 to 25 (0.02-0.04 per 1000) with beta thalassaemia major/intermedia. These are the first evidence-based rates for sickle cell and beta thalassaemia for use in the U.K., and should underpin the future planning of services. The long-term solution to monitoring changes in the rates of trait and disease in the population is to introduce a standardized instrument for collecting ethnicity for all community screening programmes.

Entities:  

Mesh:

Year:  1999        PMID: 10192451     DOI: 10.1046/j.1365-2141.1999.01275.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  27 in total

1.  Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry.

Authors:  B Modell; R Harris; B Lane; M Khan; M Darlison; M Petrou; J Old; M Layton; L Varnavides
Journal:  BMJ       Date:  2000-02-05

2.  A stochastic model to evaluate options for antenatal genetic screening.

Authors:  Steve Gallivan; Mark Jit; Martin Utley
Journal:  Health Care Manag Sci       Date:  2006-05

3.  The epidemiology of abnormal hemoglobins in Mediterranean high-level athletes.

Authors:  Imed Touhami; Slaheddine Fattoum; Amina Bibi; Hajer Siala; Taieb Messaoud; Donia Koubaa; Rafik Mankai; Zakia Bartagi; Daniel Le Gallais
Journal:  Eur J Appl Physiol       Date:  2009-12-16       Impact factor: 3.078

4.  Hemoglobinopathies: a longitudinal study over four decades.

Authors:  Elisabeth Kohne; Enno Kleihauer
Journal:  Dtsch Arztebl Int       Date:  2010-02-05       Impact factor: 5.594

Review 5.  Treatments for priapism in boys and men with sickle cell disease.

Authors:  Francis I Chinegwundoh; Sherie Smith; Kofi A Anie
Journal:  Cochrane Database Syst Rev       Date:  2017-09-19

Review 6.  Sickle cell disease.

Authors:  Martin M Meremikwu; Uduak Okomo
Journal:  BMJ Clin Evid       Date:  2011-02-14

7.  Respect, trust, and the management of sickle cell disease pain in hospital: comparative analysis of concern-raising behaviors, preliminary model, and agenda for international collaborative research to inform practice.

Authors:  James Elander; Mary Catherine Beach; Carlton Haywood
Journal:  Ethn Health       Date:  2011 Aug-Oct       Impact factor: 2.772

8.  Global epidemiology of haemoglobin disorders and derived service indicators.

Authors:  Bernadette Modell; Matthew Darlison
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

Review 9.  Sickle cell disease.

Authors:  Martin M Meremikwu
Journal:  BMJ Clin Evid       Date:  2009-03-27

Review 10.  Sickle cell anaemia: epidemiology and cost of illness.

Authors:  Paul J Nietert; Marc D Silverstein; Miguel R Abboud
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.